Mutations in the NRAS gene play a critical role in the development and progression of several cancers, most notably melanoma and colorectal cancer. Found in 15–25% of melanomas and 2–6% of colorectal tumours, NRAS mutations are associated with resistance to targeted therapies and are recognised as negative prognostic markers in metastatic disease. In colorectal cancer, NRAS mutation detection in KRAS wild-type patients guides treatment selection and rules out resistance to EGFR-targeted therapy, while in melanoma, these mutations serve as poor prognostic markers and emerging therapeutic targets for novel treatment strategies.
To address this important clinical need, Genes2Me introduces the NRAS-Q Real-Time PCR Kit — an advanced in vitro diagnostic solution designed for the sensitive and specific detection of nine clinically significant NRAS mutations across codons 12, 13, 59, 61, 117, and 146 in exons 2, 3, and 4. Validated for use with FFPE and fresh clinical samples, it is an ideal tool for both routine diagnostics and advanced molecular oncology applications.
The NRAS-Q Kit employs allele-specific Real-Time PCR technology with mutation-targeted FAM probes and an integrated HEX-labeled quality control probe. This dual-probe system ensures precise mutation detection while continuously monitoring for DNA quality and PCR inhibition, minimising false-negative results. The assay workflow incorporates seven ready-to-use mixes — including mutation panels, quality control, enzyme mix, and positive control — ensuring robust performance, reproducibility, and ease of use across routine and advanced diagnostic settings.
NRAS mutation testing is an established component of precision oncology work-up in colorectal cancer and melanoma. Accurate detection of NRAS mutations supports clinician decision-making across patient stratification, targeted therapy selection, and avoidance of ineffective treatments. By integrating molecular profiling into routine practice, the NRAS-Q Kit helps clinicians tailor treatment plans and improve patient outcomes. With high sensitivity and specificity for low-frequency variants, and comprehensive coverage across nine clinically relevant mutations in exons 2, 3, and 4, the kit provides laboratories with dependable molecular diagnostic performance to support the global shift towards personalised oncology care.
Detects nine clinically relevant NRAS mutations across codons 12, 13, 59, 61, 117, and 146 in exons 2, 3, and 4.
Allele-specific amplification with FAM-labeled mutation probes enables reliable detection of low-frequency NRAS variants.
Integrated HEX-labeled quality control probe continuously monitors DNA quality and PCR inhibition in every run, minimising false-negative results.
Seven pre-mixed reagent mixes including mutation panels, quality control, enzyme mix, and positive control simplify setup and reduce the risk of errors.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Validated for use with both FFPE and fresh clinical tissue samples, suitable for routine diagnostics and advanced molecular oncology applications.
With the NRAS-Q Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful detection of NRAS somatic mutations. By supporting accurate mutation profiling, targeted therapy selection, and improved clinical evaluation across melanoma and colorectal cancer, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the NRAS-Q Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
NRAS-Q Real Time PCR specific amplification plot of Treponema pallidum Positive Control (HEX Channel) along with Internal Control (Cy5 Channel)
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| NRAS-Q Real-Time PCR Kit | G610023-1 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
